---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: CDX0159-17"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: CDX0159-17. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 20 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence/cdx0159-17"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: CDX0159-17

<a id="heading-3.1.3"></a>

## 3.1.3 CDX0159-17

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of this extension study is to collect long-term efficacy and safety data on barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who completed the treatment and follow-up periods of the Phase 3 clinical trials.”
> “This study will also fulfill the Celldex commitment to provide post-trial access to participants who have completed the phase 3 studies, where applicable.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.1-2"></a>

#### Official title in the ClinicalTrials.gov record

> “A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.1-3"></a>

#### Time to disease worsening as the aim in the detailed description

> “This is a global, multicenter, long-term extension phase 3b study to determine the time to disease worsening or treatment failure in adult participants with Chronic Spontaneous Urticaria (CSU) who completed the treatment and follow-up periods the phase 3 clinical trials.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Enrolling by invitation”
> “Study Start (Actual) 2025-11-25”
> “Primary Completion (Estimated) 2028-09”
> “Study Completion (Estimated) 2028-09”
> “First Posted 2025-12-01”
> “Last Update Posted 2026-11-02”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.2-2"></a>

#### Number of locations in the ClinicalTrials.gov record

> “This study has 201 locations”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.2-3"></a>

#### Long-term extension established and ongoing at the phase 3 topline

> “A global Phase 3b long term extension study (LTE) has been established and is ongoing, which patients can enter following completion of the EMBARQ-CSU Phase 3 trials.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Design in the ClinicalTrials.gov record

> “Allocation : Non-Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : None (Open Label)”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.3-2"></a>

#### Observation and retreatment groups assigned by UAS7 at entry, and duration of participation

> “The study will consist of 2 Groups: Group 1 (Observation Group), comprising participants whose UAS7 score is less than 16 at entry and Group 2 (Barzolvolimab Retreatment Group) comprising participants whose UAS7 score is 16 or greater.”
> “Participation in this trial will last for approximately 52 weeks for participants assigned to Group 1 (Observation Group) and who do not receive barzolvolimab during the trial. Participants assigned to Group 1 who require barzolvolimab rescue during the trial will be in the trial for up to 68 weeks. Participants assigned to Group 2 (Barzolvolimab Retreatment Group), trial participation will last for approximately 68 weeks from the start of treatment (Day 1).”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.3-3"></a>

#### Observation and retreatment groups described in the Form 10-Q

> “In addition, a global Phase 3b long term extension (LTE) study has been established for patient entry after completion of the EMBARQ - CSU Phase 3 trials.”
> “The study will consist of 2 Groups: Group 1 (Observation Group), containing patients whose disease remains well controlled (UAS7<16) and Group 2 (Barzolvolimab Retreatment Group) containing patients whose disease is currently moderate to severe (UAS7≥16).”
> “Patients in Group 2 will receive up to an additional year of treatment with barzolvolimab.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Key inclusion criteria in the ClinicalTrials.gov record

> “Must have successfully completed the preceding phase 3 clinical trials (CDX0159-12 or CDX0159-13).”
> “Both males and females of child-bearing potential must agree to use highly effective contraceptives when receiving barzolvolimab treatment and for 150 days after treatment.”
> “Willing and able to comply with all study requirements and procedures, including completion of a daily symptom electronic diary.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.4-2"></a>

#### Key exclusion criteria in the ClinicalTrials.gov record

> “Active pruritic skin condition in addition to CSU.”
> “Medical condition that would cause additional risk or interfere with study procedures.”
> “Participants without at least one documented UAS7 score from Weeks 64-68 of the CDX0159-12 or CDX0159-13 trials.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Groups and interventions in the ClinicalTrials.gov record

| Group | Description in the record |
| --- | --- |
| Group 1, observation | “Standard of care treatment (at least 2nd generation Type 1 antihistamines [H1AH] with or without other permitted background medications) for 52 weeks.” |
| Group 1, rescue for worsening disease | “For participants with worsening disease (UAS7 score of 16 or greater at any time between Weeks 0-24), barzolvolimab will be administered once as a 300 mg subcutaneous injection followed by 150 mg every 4 weeks for up to 52 weeks.” |
| Group 2, retreatment | “Barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Barzolvolimab intervention | “Subcutaneous Administration” |
| Standard of care intervention | “Observational/Standard of Care” |

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.5-2"></a>

#### Treatment of observation group participants whose disease flares in the first 6 months

> “Patients in the observation group (Group 1) whose CSU flares to a UAS7>/=16 in the first 6 months of the LTE will also be able to receive treatment.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Time to Disease Worsening as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Primary outcome measures in the ClinicalTrials.gov record

> “Time to disease worsening or treatment failure through Week 52 based on the occurrence of UAS7 (Urticaria Activity Score) of 16 or greater.”
> “Time to disease worsening or treatment failure through Week 52 based on the occurrence of the discontinuation of barzolvolimab in Group 2 due to lack of efficacy or to a treatment related adverse event.”
> “Time to disease worsening or treatment failure through Week 52 based on the occurrence of first use of strongly confounding prohibited medication (Group 1 or 2) or use of barzolvolimab in Group 1.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.6.1-2"></a>

##### Definition of the UAS7 in the ClinicalTrials.gov record

> “The UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.6.1-3"></a>

##### Secondary outcome measures for the observation group (Group 1)

> “Group 1: Change from baseline in Urticaria Activity Score (UAS7) at Week 26.”
> “Group 1: Change from baseline in UAS7 at Week 52/End of Study.”
> “Group 1: Proportion of participants who maintained at least well-controlled disease (UAS7 ≤ 6) at Week 26.”
> “Group 1: Proportion of participants who maintained at least well-controlled disease (UAS7 ≤ 6) at Week 52.”
> “Group 1: Proportion of participants with complete absence of hives and itch (UAS7 = 0 AAS7 = 0) at Day 1 who maintained complete control at Week 26.”
> “Group 1: Participants with at least well-controlled disease (UAS7 ≤ 6) at Day 1, time to loss of well-controlled disease through Week 52.”
> “Group 1: Participants with complete absence of hives and itch (UAS7 = 0) at Day 1, time to loss of complete controlled disease through Week 52.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.6.1-4"></a>

##### Secondary outcome measures for the retreatment group (Group 2)

> “Group 2: Change from baseline in UAS7 at Week 12.”
> “Group 2: Change from baseline in UAS7 at Week 68.”
> “Group 2: Proportion of participants with at least well-controlled disease (UAS7 ≤ 6) at Week 12.”
> “Group 2: Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12.”
> “Group 2: Percentage of participants with UAS7 = 0 at Week 52.”
> “Group 2 Incidence of treatment emergent adverse events.”
> “Group 2 Incidence of treatment emergent adverse events leading to treatment discontinuation.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="topic-3.1.3.6.1-5"></a>

##### Safety outcome measures for the observation group (Group 1)

> “Group 1 Incidence of adverse events.”
> “Group 1 Incidence of treatment emergent adverse events in participants receiving barzolvolimab retreatment.”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 1370”

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

No evidence found.

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary: limitations of the available long-term extension evidence

- The phase 3b long-term extension (NCT07256392) started 2025-11-25, is enrolling by invitation, and has an estimated primary completion of 2028-09. No disposition, baseline, efficacy, quality of life, or safety results have been reported.
- The design is non-randomized and open label. Participants are assigned by UAS7 at entry: those with UAS7 below 16 enter an observation group on standard of care (at least second-generation H1 antihistamines), and those with UAS7 of 16 or greater enter a barzolvolimab retreatment group.
- Retreatment and rescue of observation-group participants with worsening disease both use a 300 mg loading dose followed by 150 mg every 4 weeks; the 300 mg every 8 weeks regimen of the phase 3 trials is not among the extension's interventions.
- Enrollment is limited to participants who completed the preceding phase 3 trials (CDX0159-12 or CDX0159-13) and have at least one documented UAS7 score from Weeks 64 to 68 of those trials.
- The primary endpoint is time to disease worsening or treatment failure through Week 52, defined by UAS7 of 16 or greater, discontinuation of barzolvolimab in the retreatment group for lack of efficacy or a treatment-related adverse event, or first use of a strongly confounding prohibited medication or of barzolvolimab in the observation group. Estimated enrollment is 1370.

Source: [ClinicalTrials.gov NCT07256392](https://clinicaltrials.gov/study/NCT07256392); [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and); [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
